{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010278","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.500786+00:00","generated_at":"2026-05-31T10:12:05.096515+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tenax Therapeutics closes $100M private placement to fund Phase 3 levosimendan program","bullets":["Gross proceeds of ~$100M from oversubscribed private placement led by BVF Partners.","Issued 1,450,661 common shares at $3.00, plus pre-funded warrants for 31,882,671 shares and warrants for 16,666,666 shares.","Funds will complete ongoing LEVEL Phase 3 study and initiate a second Phase 3 study in 2025, shortening NDA timeline.","Oral levosimendan (TNX-103) targets PH-HFpEF, a disease with no approved therapies; earlier HELP study showed 29-meter 6MWD improvement.","Leerink Partners, Guggenheim Securities, and William Blair acted as placement agents; ROTH Capital advised Tenax."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010278","json":"https://secwatch.observer/filing/0001654954-24-010278.json","markdown":"https://secwatch.observer/filing/0001654954-24-010278.md","text":"https://secwatch.observer/filing/0001654954-24-010278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/0001654954-24-010278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424010278/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:12:05.096515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}